Biopharmaceutical
Pharmaceutical
Health

Esperion Therapeutics

844

$30.76
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$2.21 (-6.70%) Today
$0.00 (0.00%) As of 8:00 PM EDT after-hours

Why Robinhood?

You can buy or sell ESPR and other stocks, options, ETFs, and crypto commission-free!

About ESPR

Esperion Therapeutics, Inc. engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. It offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. Read More The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.

CEO
Tim M. Mayleben
Employees
193
Headquarters
Ann Arbor, Michigan
Founded
1998
Market Cap
846.27M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
714.51K
High Today
$33.79
Low Today
$29.90
Open Price
$32.05
Volume
680.79K
52 Week High
$76.98
52 Week Low
$24.82

Collections

Biopharmaceutical
Pharmaceutical
Health
Research And Development
Therapy
Biotechnology
Medical
Technology

ESPR News

ReutersMar 30

BRIEF-Esperion Announces Commercial Availability Of Nexletol Tablet

March 30 (Reuters) - Esperion Therapeutics Inc: * ESPERION ANNOUNCES COMMERCIAL AVAILABILITY OF THE NEXLETOLâ„¢ (BEMPEDOIC ACID) TABLET AND PLEDGES A CONSCIENTIO
75

ESPR Earnings

-$2.67
-$0.76
$1.16
$3.07
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Estimated
— per share
Actual
Expected May 6, Pre-Market

People Also Bought

Amarin

36,283

$4.73

-9.39%

Amarin

36,283

$4.73

-9.39%

Stmicroelectronics

7,134

$19.22

-3.85%

Sea Limited

5,476

$42.00

-5.79%

Glu Mobile

51,453

$5.95

-4.49%

You May Also Like

BSGM
BX
NBTB
BMWYY
HHC
CNFR
OIA
ANAB
INDY
SMMT
Robinhood Snacks newsletters and podcasts reflect the opinions of only the authors who are associated persons of Robinhood Financial LLC and do not reflect the views of Robinhood Markets, Inc. or any of its subsidiaries or affiliates. They are meant for informational purposes only, are not intended to serve as a recommendation to buy or sell any security in a self-directed Robinhood account or any other account, and are not an offer or sale of a security. They are also not research reports and are not intended to serve as the basis for any investment decision. Any third-party information provided therein does not reflect the views of Robinhood Markets, Inc., Robinhood Financial LLC, or any of their subsidiaries or affiliates. All investments involve risk and the past performance of a security or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit or protect against loss. There is always the potential of losing money when you invest in securities or other financial products. Investors should consider their investment objectives and risks carefully before investing. The price of a given security may increase or decrease based on market conditions and customers may lose money, including their original investment. Robinhood Financial LLC, member FINRA/SIPC.

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.

Buy ESPR

Market Price$30.76
Commissions$0.00
Estimated Cost
$0.00
Sign up for a Robinhood Account to buy or sell ESPR stock and options commission-free.
Search
LearnBlogCareersHelpLog InSign Up